4//SEC Filing
Sagent Pharmaceuticals, Inc. 4
Accession 0000899243-16-028311
CIK 0001369786operating
Filed
Aug 30, 8:00 PM ET
Accepted
Aug 31, 6:24 PM ET
Size
27.6 KB
Accession
0000899243-16-028311
Insider Transaction Report
Form 4
BULLOCK DONALD R
Executive V.P. Sales
Transactions
- Disposition to Issuer
Stock Option to Buy
2016-08-29$1.59/sh−3,546$5,638→ 0 totalExercise: $20.16Exp: 2024-02-18→ Common Stock (3,546 underlying) - Disposition to Issuer
Stock Option to Buy
2016-08-29$10.15/sh−5,103$51,795→ 0 totalExercise: $11.60Exp: 2020-12-02→ Common Stock (5,103 underlying) - Disposition to Issuer
Common Stock
2016-08-29$21.75/sh−8,073$175,588→ 0 total - Disposition to Issuer
Stock Option to Buy
2016-08-29$6.73/sh−10,608$71,392→ 0 totalExercise: $15.02Exp: 2026-06-27→ Common Stock (10,608 underlying) - Disposition from Tender
Common Stock
2016-08-29$21.75/sh−2,583$56,180→ 8,073 total - Disposition to Issuer
Stock Option to Buy
2016-08-29$19.24/sh−607$11,679→ 0 totalExercise: $2.51Exp: 2017-08-10→ Common Stock (607 underlying) - Disposition to Issuer
Stock Option to Buy
2016-08-29$7.14/sh−6,522$46,567→ 0 totalExercise: $14.61Exp: 2026-02-22→ Common Stock (6,522 underlying) - Disposition to Issuer
Stock Option to Buy
2016-08-29$5.30/sh−9,969$52,836→ 0 totalExercise: $16.45Exp: 2023-02-21→ Common Stock (9,969 underlying) - Disposition to Issuer
Stock Option to Buy
2016-08-29$17.44/sh−5,103$88,996→ 0 totalExercise: $4.31Exp: 2019-12-11→ Common Stock (5,103 underlying) - Disposition to Issuer
Stock Option to Buy
2016-08-29$17.52/sh−6,870$120,362→ 0 totalExercise: $4.23Exp: 2018-08-15→ Common Stock (6,870 underlying)
Footnotes (10)
- [F1]Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these shares were disposed of in a cash tender offer by Shepard Vision, Inc. to acquire common stock of Sagent Pharmaceuticals, Inc. in exchange for $21.75 per share in cash, without interest, less any applicable withholding taxes (the "Consideration").
- [F10]Represents the disposition of options, which provided for vesting in four equal installments beginning August 10, 2008. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $19.24 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
- [F2]Pursuant to the Merger Agreement, these restricted shares were canceled and converted into the right to receive the Consideration.
- [F3]Represents the disposition of options, which provided for vesting in four equal installments beginning June 27, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $6.73 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
- [F4]Represents the disposition of options, which provided for vesting in four equal installments beginning February 22, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $7.14 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
- [F5]Represents the disposition of options, which provided for vesting in four equal installments beginning February 18, 2015. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1.59 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
- [F6]Represents the disposition of options, which provided for vesting in four equal installments beginning February 21, 2014. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $5.30 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
- [F7]Represents the disposition of options, which provided for vesting in four equal installments beginning December 2, 2011. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $10.15 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
- [F8]Represents the disposition of options, which provided for vesting in four equal installments beginning December 11, 2010. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $17.44 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
- [F9]Represents fully vested performance options. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $17.52 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
Documents
Issuer
Sagent Pharmaceuticals, Inc.
CIK 0001369786
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001369786
Filing Metadata
- Form type
- 4
- Filed
- Aug 30, 8:00 PM ET
- Accepted
- Aug 31, 6:24 PM ET
- Size
- 27.6 KB